Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abeona Therapeutics's enterprise value is $216.67 Mil.
Abeona Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-71.30 Mil. Therefore, Abeona Therapeutics's EV-to-EBITDA for today is -3.04.
The historical rank and industry rank for Abeona Therapeutics's EV-to-EBITDA or its related term are showing as below:
LTS:0H7R'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.56 Med: -1.47 Max: 3.51
Current: -3.04
During the past 13 years, the highest EV-to-EBITDA of Abeona Therapeutics was 3.51. The lowest was -28.56. And the median was -1.47.
LTS:0H7R's EV-to-EBITDA is ranked worse than 100% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs LTS:0H7R: -3.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abeona Therapeutics's PE Ratio (TTM) for today is calculated as:
Abeona Therapeutics's share price for today is $5.94.
Abeona Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Abeona Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H7R vs STRO, IKT, AGEN: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Abeona Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's EV-to-EBITDA falls into.
Abeona Therapeutics's current Enterprise Value is $216.67 Mil.
Abeona Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (LTS:0H7R) has a EV-to-EBITDA of -3.04 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abeona Therapeutics. According to the industry distribution chart, Abeona Therapeutics ranks #999999 out of 399 companies in the Biotechnology industry.
Is Abeona Therapeutics' EV-to-EBITDA too high?
Abeona Therapeutics' current EV-to-EBITDA is -3.04. Based on the distribution chart, Abeona Therapeutics ranks #999999 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abeona Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' EV-to-EBITDA compare to STRO and IKT?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #999999 out of 399 companies for EV-to-EBITDA. This places Abeona Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abeona Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abeona Therapeutics's current EV-to-EBITDA is -3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (LTS:0H7R) is currently considered Possible Value Trap. The stock's GF Value™ is $20.82, compared to a current price of $5.94 — trading 71.5% below its estimated fair value. The current EV-to-EBITDA is -3.04. Abeona Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Abeona Therapeutics (LTS:0H7R), the current EV-to-EBITDA is -3.04 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abeona Therapeutics (LTS:0H7R) Overvalued in 2026?
Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued.
The current stock price of $5.94 is trading 71.5% below its estimated GF Value™ of $20.82.
GuruFocus considers Abeona Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0H7R:
EV-to-EBITDA: -3.04
GF Value™: $20.82 vs. price of $5.94 (71.5% below fair value)
No single metric tells the full story. See the LTS:0H7R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
46GF Score
Get the complete analysis for LTS:0H7R
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H7R has been successfully added to your 
